DaVita Inc. (NYSE:DVA) Given Consensus Rating of “Hold” by Analysts

DaVita Inc. (NYSE:DVA) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $166.33.

A number of analysts recently commented on the company. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. Barclays raised their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. StockNews.com raised shares of DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Finally, Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th.

Hedge Funds Weigh In On DaVita

Several large investors have recently modified their holdings of the business. UMB Bank n.a. boosted its holdings in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $29,000 after buying an additional 76 shares during the period. Copia Wealth Management bought a new position in shares of DaVita in the fourth quarter worth $30,000. SBI Securities Co. Ltd. purchased a new position in shares of DaVita in the fourth quarter valued at $41,000. Coppell Advisory Solutions LLC raised its stake in shares of DaVita by 50.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after purchasing an additional 100 shares during the period. Finally, Canada Post Corp Registered Pension Plan purchased a new stake in DaVita during the 4th quarter worth about $55,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

DVA opened at $140.91 on Friday. The firm’s fifty day moving average price is $146.04 and its two-hundred day moving average price is $154.53. The company has a market capitalization of $11.27 billion, a price-to-earnings ratio of 13.12, a P/E/G ratio of 1.07 and a beta of 1.04. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita has a 1 year low of $131.44 and a 1 year high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, analysts anticipate that DaVita will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.